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Available online 1 December 2015Five new mononuclear Pt(II) complexes with 5-perﬂuoroalkyl-1,2,4-oxadiazolyl-pyridine and 3-perﬂuoroalkyl-
1,2,4-triazolyl-pyridine ligands are reported. The ligands 2-(5-perﬂuoroheptyl-1,2,4-oxadiazole-3yl)-pyridine
(pfhop), 2-(5-perﬂuoropropyl)-1,2,4-oxadiazole-3yl)-pyridine (pfpop), 2-(3-perﬂuoroheptyl-1-methyl-1,2,4-
triazole-5yl)-pyridine (pfhtp), 2-(3-perﬂuoropropyl-1-methyl-1,2,4-triazole-5yl)-pyridine (pfptp) and their
complexes [PtCl2(pfhop)2]·1.5 DMSO (2a), [PtCl2(pfpop)2]·1.5 DMSO (3a), [PtCl2(pfhtp)2]·1.5 DMSO (4a),
PtCl2(pfhtp) (4b), [PtCl2(pfptp)2]·1.5 DMSO (5a) have been synthesized and structurally characterized. The
complexes 2a, 3a, 4a and 5a have the same chemical environment of Pt(II) where PtCl2 moieties coordinate
two molecules of ligand via N1 atom of pyridine in the case of pfhop and pfpop, and N2 atom of 1,2,4-triazole
in the case of pfhtp and pfptp. For 4b, pfhtp behaves as bidentate ligand, coordinating Pt(II) ion via N4 atom
of triazole and N1 atom of pyridine. All complexes have been tested in vitro by 3-(4,5-dimethyl-2-
thiazolyl)bromide-2,5-diphenyl-2 H-tetrazolium (MTT) test on four tumor cell lines MCF-7 (human breast can-
cer), HepG2 (human hepatocellular carcinoma), HCT116 (human colorectal carcinoma). Compounds 2a and 4b
showed a dose-dependent anti-proliferative effect against the three tumor cell lines whereas did not affect via-
bility of intestinal normal-like differentiated Caco-2 cells. The cell death of HepG2, MCF-7 and HCT116 induced
by the compounds, was considered to be apoptotic by measuring the exposure of phosphatidylserine to the
outer membrane and observing the typical apoptotic morphological change by acridine orange (AO)/ethidium
bromide (EB) staining.
© 2015 Elsevier Inc. All rights reserved.Keywords:
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In the last decades, the successful application of cisplatin antitumor
therapies has triggered considerable interest in the search for more af-
fective cisplatin analogs. Many efforts have been dedicated to explain
the factors related to the anticancer activity of cisplatin and different
platinum compounds [1,2] and although the molecular mechanistic
studies of cisplatin and analogs have been largely developed, the cellular
response to these compounds is still poorly understood [3,4].imethylformamide; DMSO,
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isothiocyanate; GC/MS, Gas
esolution Mass; MTT, 3-(4,5-
etrazolium; PBS, phosphate
erine; RPMI, Roswell Park
; TMS, tetramethylsilane.
, ivana.pibiri@unipa.it (I. Pibiri).Several studies have been conducted with common goals, such as
the design of new metal complexes that keep active against resistant
cell lines, with a large spectrum of anticancer activity and also with a
lower toxicity than cisplatin [5]. However, the cross resistance and se-
vere side effects of platinum drugs, such as nephrotoxicity, have limited
their clinical application. In the past years, successful approaches have
been employed to solve these drawbacks, combining platinum-based
drugs with some other active pharmacophore so that a synergic action
can be obtained [6]. Oxadiazole and triazole have been recently used
for complexation of metal such as copper, nickel [7], palladium [8] and
platinum [9]; 1,2,4-oxadiazoles have been widely studied for their chem-
istry [10–12], these heterocycles have gained attention for their pharma-
ceutical properties, and additionally, the presence of the ﬂuorinated
moiety opens the way to new ﬂuorine-induced activity with respect to
corresponding non-ﬂuorinated systems [13–16] and application inmate-
rials [17–21]. In particular, a series of Pt(II) complexes with 1,2,4-
oxadiazole derivatives as ligands have shown cytotoxic activity towards
human ovarian cancer, and also in colon and testicular cancer cell lines.
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the sameway, triazole rings have been widely studied as bioactive moie-
ties [23] and alsohavebeenused as ligands in order to synthesize cytotox-
ic platinum, palladium and organotin(IV) complexes [24–27].
In this paper, we report the synthesis and characterization of new
platinum complexes and the synthesis of the new ligands: pfhop,
pfpop, pfhtp and pfptp. In 2a and 3a complexes, the coordination of
2-(5-perﬂuoroalkyl-1,2,4-oxadiazol-3yl)-pyridine ligands involve the
N1 atom of pyridine, acting as monodentate ligand, as already observed
in the literature for Cu(II), Co(II) and Ni(II) complexes with 2,5-bis(2-
pyridyl)-1,3,4-oxadiazolyl-pyridine [7]. The coordination of Pt(II) ion
to the 2-(3-perﬂuoroalkyl-1-methyl-1,2,4-triazole-5yl)-pyridine li-
gands for 4a and 5a complexes, occurs via N2 atoms of two 1,2,4-tri-
azole moieties as already observed in the literature for azole-bridged
dinuclear platinum(II) complexes [24]. On the contrary, in the case of
4b, only one molecule of 1,2,4-triazolyl-pyridine is coordinated to
Pt(II) ion via N4 atomof triazolemoiety andN1 atomof pyridine respec-
tively, where the ligand is bidentate as reported in literature with Pt(II)
and Pd(II) ions [8]. Cytotoxicity in vitro of the synthesized cisplatin an-
alogs was evaluated by MTT test on three tumor human cell lines:
HepG2, MCF-7 and HTC116. The calculated IC50 values of 2a and 4b
complexes show that antiproliferative activity of both the cisplatin
analogswas comparable to that observedwith cisplatin, being 2a signif-
icantly more effective than 4b against all the selected cancer cells.
Mechanismof the anti-proliferative effect of 2a and 4bwas investigated
by double staining with propidium iodide (PI) and Annexin V-
Fluorescein isothiocyanate (FITC) followed by cytoﬂuorimetric analysis
and shows that 2a and 4b complexes induce a clear shift of viable cells
towards early apoptosis in HepG2 and HCT116 or towards late apopto-
sis in MCF-7 cells.
2. Experimental
2.1. General methods
All solvents and reagents were obtained from commercial sources
(Sigma-Aldrich). Cis-[PtCl2(DMSO)2] [28] and N-hydroxypicolinamidine
1 (95% yields, m.p. 116–118 °C)were synthesized according to previously
reportedmethod [29]. Syntheseswere performedwith exclusion ofmois-
ture and direct light. Elemental analysis for C, H, N, were performed at the
Laboratorio di Microanalisi (University of Padova, Italy); chlorinewas de-
termined by potentiometric titration with standard silver nitrate after
combustion in pure oxygen according to Schöniger [30]. The percentage
of platinum in the complexes has been measured by a Perkin–Elmer
372 atomic absorption spectrometer against the appropriate standards.
IR spectra (Nujol) were registered with a Shimadzu FTIR-8300 instru-
ment. 1H NMR spectra were recorded on a Bruker 300 Avance spectrom-
eter, operating at 300 MHz, with tetramethylsilane (TMS) as an internal
standard. The molar conductivities for all complexes were determined
in DMSO at 10−3 M at 25 °C with a Crison GLP 31Model Conductometer.
Gas Chromatography/Mass Spectrometry (GC/MS) spectra were deter-
mined with a Shimadzu QP-2010 instrument. High Resolution Mass
(HRMS) were determined by Agilent Technologies 6540 UHD Accurate-
Mass Q-TOF LC/MS instrument. Melting points were determined on a
Koﬂer plate with Reichart–Thermovar hotstage apparatus and are uncor-
rected. Flash chromatography was performed by using silica gel (Merck,
0.040–0.063 mm) and mixtures of ethyl acetate and petroleum (fraction
boiling in the range 40–60 °C) in various ratios.
2.2. Synthesis of ligands
2.2.1. General method of synthesis of 1,2,4-oxadiazolyl-pyridines
The synthetic approach for the preparation of substituted 1,2,4-
oxadiazoles derivatives is shown in Scheme 1. N-hydroxypicolinamidine
1 (1 g) was dissolved in toluene (60 ml) in a round-bottomed ﬂask, andthen pyridine (1 ml) and appropriate acyl chloride (1.2 equivalent)
were added.
The reaction mixture was allowed to reﬂux for 6–8 h and was mon-
itored by thin layer chromatography (TLC) until the reaction was
complete. The solvent was removed under vacuum, and then the resi-
due was added with water (60 ml) and extracted with ethyl acetate
(50 ml × 3). The organic layer was dried over anhydrous Na2SO4, and
solvent was removed under vacuum. The residue was puriﬁed through
silica gel column chromatography using a mixture of ethyl acetate and
petroleum as eluent to afford the desired oxadiazolyl-pyridine [31–32].
2.2.2. 2-(5-perﬂuoroheptyl-1,2,4-oxadiazol-3-yl)-pyridine (pfhop) (2)
The compound 2was prepared following the general procedure, by
reacting N-hydroxypicolinamidine 1 (1.015 g, 7.293 mmol) and
pentadecaﬂuorooctanoyl chloride (2.170 ml, 8.752 mmol). The product
was obtained as a yellow solid in 70% yield, m.p. 74–76 °C. 1H NMR
(CD3CN, 300 MHz) δ ppm: 8.79 (d, J = 4.5 Hz, 1H, Pyridyl), 8.14 (d,
J = 7.8 Hz, 1H, Pyridyl), 8 (dt, J = 1.82 e 7.8 Hz, 1H, Pyridyl), 7.6 (dd,
J = 4.76 e 7.8 Hz, 1H, Pyridyl); MS m/z (%) 515 (M+, 100), 166 (25),
120 (90), 78 (90), 51 (20). HRMS C14H4F15N3O [M + H] calculated
516.0187, found 516.0182.
2.2.3. 2-(5-perﬂuoropropyl-1,2,4-oxadiazol-3-yl)-pyridine (pfpop) (3)
Compound 3 was prepared following the general procedure by
reacting N-hydroxypicolinamidine 1 (1.009 g, 7.250 mmol) and
heptaﬂuorobutyryl chloride (1.299 ml, 8.700 mmol). The product
was obtained as a yellow solid in 88% yield. m.p. 87–90 °C. 1H NMR
(DMSO-d6, 300 MHz,) δ ppm: 8.85 (dd, J = 2.5 e 5.7 Hz, 1H, Pyridyl),
8.18 (dd, J = 1.8 e 8 Hz, 1H, Pyridyl), 8.10 (dt, J = 1.6 e 7.3 Hz, 1H,
Pyridyl), 7.72 (dt, J = 4.6 e 6.8 Hz, 1H, Pyridyl); MS m/z (%) 315
(M+, 100), 285 (15), 120 (75), 78 (90), 69 (20), 51 (25). HRMS
C10H4F7N3O [M + H] calculated 316.0315, found 316.0319.
2.2.4. General procedure for the synthesis of 1,2,4-triazoles
The synthetic approach for the preparation of substituted 1,2,4-
triazoles derivatives is shown in Scheme 1. To a sample of oxadiazolyl–
pyridine (1.5 mmol) in dry dimethylformamide (DMF) (2 ml) an excess
of 99% methyl hydrazine (7.5 mmol) was added and the mixture was
left at room temperature for 1 h. After dilution with water and extraction
with ethyl acetate, the combined extractswere dried overNa2SO4 and the
solvent was removed under vacuum. The residue was puriﬁed through
silica gel columnchromatographyusing amixture of ethyl acetate andpe-
troleum as eluent to afford the desired triazolyl–pyridine [32].
2.2.5. 2-(3-perﬂuoroheptyl-1-methyl-1,2,4-triazole-5-yl)-pyridine (pfhtp)
(4)
Compound 4 was prepared starting by 2-(5-Perﬂuoroheptyl-1,2,4-
oxadiazol-3-yl)-pyridine 2 (1.011 g, 1.963 mmol). The product was ex-
tracted with ethyl acetate, puriﬁed through silica gel column chroma-
tography using petroleum/ethyl acetate in ratio 6/1, affording a white
crystalline solid in 70% yield; m.p. 49–51 °C. 1H NMR (DMSO-d6,
300 MHz,) δ ppm: 8.80 (d, J = 3.75 Hz, 1H, Pyridyl), 8.17 (d, J =
6.75 Hz, 1H, Pyridyl), 8.05 (dt, J = 1.25 e 6.5 Hz, 1H, Pyridyl), 7.67 (m,
J = 4 e 6.25 Hz, 1H, Pyridyl), 4.39 (s, 3H, Me); MS m/z (%) 528
(M+,40), 527 (95), 209 (15), 159 (65), 133 (60), 106 (25), 105
(1000), 78 (35). HRMS C15H7F15N4 [M + H] calculated 529.0504,
found 529.0510.
2.2.6. 2-(3-perﬂuoropropyl-1-methyl-1,2,4-triazole-5-yl)-pyridine (pfptp)
(5)
Compound 5 was prepared starting by 2-(5-Perﬂuoropropyl-1,2,4-
oxadiazol-3-yl)-pyridine 3 (1.855 g, 5.655 mmol). The product was ex-
tractedwith ethyl acetate, chromatographedwith light petroleum/ethyl
acetate in ratio 6/1, affording an oil in 78% yield; 1H NMR (DMSO-d6,
300 MHz) δ ppm: 8.79 (d, J = 4.6 Hz, 1H, Pyridyl), 8.16 (d, J = 7.3 Hz,
1H, Pyridyl), 8.05 (dt, J = 1.7 e 7.3 Hz, 1H, Pyridyl), 7.61 (dd, J = 4.4 e
Scheme 1. Synthesis of the ligands 2–5.
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159 (40), 133 (50), 105 (100), 78 (40). HRMS C11H7F7N4 [M+H] calcu-
lated 329.0631, found 329.0635.
2.3. General procedures of synthesis of complexes (2a), (3a), (4a), (5a)
Cis-[PtCl2(DMSO)2] (0.174 g, 0.4 mmol) and the ligands 2, 3, 4, 5
respectively, were dissolved in 25 ml of chloroform under 1:1Scheme 2. Synthesis of platinum complexes: Rstoichiometry. The resulting solution was stirred for 24 h at 40 °C. The
yellow solids were ﬁltered, washed with chloroform and dried in
vacuo over P4O10. The synthesis of the complexes can be summarized
in Scheme 2.
2.3.1. [PtCl2(pfhop)2]·1.5 DMSO (2a)
The complex 2awasprepared following the general procedure. Yield
60%. Anal. Calc. for (C30H14N6O3SF30PtCl2)·0.5 DMSO: C, 26.34; H, 1.21;F = C7F15 (2a, 4a, 4b); RF = C3F7 (3a, 5a).
Fig. 1. Cytotoxic effect of the synthesized cisplatin analogs onHep-G2 cells (A), MCF-7 (B) or HCT116 (C) cells as assessed byMTT. Cell monolayers were incubated for 24 h in the absence
(control) or in the presence of the compounds at the indicated concentrations and cell viability was assessed byMTT test as reported in Experimental. Results are indicated as the percent-
age of viable cells with respect to untreated controls. Values are the mean ± SD of three separate experiments carried out in triplicate.
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3.00; Cl, 5.03; Pt, 13.90%. Melting point: N350 °C (decomp.). ΛM =
15.30 Ω−1 cm2 mol−1 (indicative of neutral complex) [33]. IR (cm−1)Fig. 2. Inhibitory effect of the complexes 2a or 4b on the growth of HepG2 (A), MCF-7 (B) or HCT
trol) or in the presence of 2a or 4b at 1 μM(HCT116) or in the presence of 2a or 4b at 5 μM(Hep
are indicated as the percentage of viable cells with respect to untreated controls. Values are thfor free ligand: 1591 v(CH_N), 1214–1150 v(C–F), and for the complex
1534 v(CH_N), 1628 v(C_N), 1241–1144 v(C–F), 1023 v(S_O of non-
coord. DMSO), 342 e 326 v(Pt–Cl) and 279, 256 v(Pt–N). 1HNMR for the116 (C) cells. Cell monolayerswere incubated for the indicated times in the absence (con-
G2 andMCF-7). Cell viability was assessed byMTT test as reported in Experimental. Results
e mean ± SD of three separate experiments carried out in triplicate.
Fig. 3. Effect of the complexes 2a or 4b on viability of intestinal normal-like differentiated
Caco-2 cells. Cell monolayers were incubated for 24 h in the absence (control) or in the
presence of the compounds at the indicated concentrations and cell viability was assessed
by MTT test as reported in Experimental. Results are indicated as the percentage of viable
cells with respect to untreated controls. Values are themean± SD of two separate exper-
iments carried out in triplicate.
Table 1
Calculated IC50 (μM) values for anti-proliferative activity of 2a and 4b cisplatin derivatives
against different human cell lines.
IC50 ± SD (μM)
HepG2 MCF-7 HCT 116
2a 20.2 ± 1.8 4.0 ± 0.2 1.1 ± 0.06
4b 24.8 ± 2.0 18.5 ± 1.1 8.3 ± 0.7
Cisplatin 50.0 ± 3.1 8.1 ± 0.5 9.1 ± 0.8
Values are the mean ± SD of three separate experiments carried out in triplicate.
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C5HC5ʹH), 7.78 (d, 2H, C3HC3ʹH), 7.68 (m, 2H, C4HC4ʹH), 2.65 (non-coord.
DMSO); 3JC3ʹHC4ʹH = 9.5 Hz; 3JC6ʹHC5ʹH = 5.8 Hz; 3JC5ʹHC4ʹH = 2.1 Hz.
2.3.2. [PtCl2(pfpop)2]·1.5 DMSO (3a)
The complex 3awasprepared following the general procedure. Yield
60%. Anal. Calc. for (C22H14N6O3F14PtCl2S)·0.5 DMSO: C, 27.26; H, 1.69;
N, 8.29; S, 4.75; Cl, 7.00; Pt, 19.25%. Found: C, 27.60; H, 1.63; N, 8.44; S,
4.82; Cl, 6.60; Pt, 18.95%. Melting point: N350 °C (decomp.). ΛM =
19.70 Ω−1 cm2 mol−1 (indicative of neutral complex) [33]. IR (cm−1)
for free ligand: 1590 v(CH_N), 1223–1159 v(C–F) and for the complex
1590, 1535 v(CH_N), 1631 v(C_N) 1216–1157 v(C–F), 333 e 320
v(Pt–Cl), 279, 257 v(Pt–N). 1H NMR for the complex (DMSO,
300 MHz) δ ppm: 9.07 (d, 2H, C6HC6ʹH), 8.34 (dt, 2H, C5HC5ʹH), 8.56
(d, 2 H, C3HC3ʹH), 8.15 (m, 2 H, C4HC4ʹH), 2.53–2.51 (s, non-coord.
DMSO); 3JC3ʹHC4ʹH = 9.5 Hz; 3JC6ʹHC5ʹH = 5.8 Hz; 3JC5ʹHC4ʹH = 2.1 Hz.
2.3.3. [PtCl2(pfhtp)2]·1.5 DMSO (4a)
The complex 4awasprepared following the general procedure. Yield
60%. Anal. Calc. for (C32H20N8F30PtCl2SO)·0.5 DMSO: C, 27.53; H, 1.61;
N, 7.78; S, 3.34; Cl, 4.93; Pt, 13.55%. Found: C, 27.93; H, 1.40; N, 8.06;
S, 3.30; Cl, 5.00; Pt, 13.15%. Melting point: N350 °C (decomp.). ΛM =
3.30 Ω−1 cm2 mol−1 (indicative of neutral complex) [33]. IR (cm−1)
for free ligand: 1590 v(CH_N), 1240–1147 v(C–F) and for the complex
1591 v(CH_N), 1242–1147 v(C–F), 1037 v(S_O), 338, 312 v(Pt–Cl),
277 v(Pt–N). 1H NMR for the complex (DMSO, 300 MHz) δ ppm: 8.85
(d, 2H, C6HC6ʹH), 8.22 (d, 2H, C3HC3ʹH), 8.11 (t, 2 H, C5HC5ʹH), 7.68 (t,
2H, C4HC4ʹH), 4.44 (s, 3H, Me), 2.61–2.57 (s, non-coord. DMSO);
3JC6ʹHC5ʹH = 5.2 Hz; 3JC4ʹHC3ʹH = 9.3 Hz, 3JC5ʹHC4ʹH = 6.0 Hz.
2.3.4. PtCl2(pfhtp) (4b)
An aqueous solution of K2PtCl4 (0.554 g, 1.05 mmol) was added
dropwise in stirring to a solution of 4 (0.436 g, 1.05mmol) in ethanol
(25ml) at 40 °C. A red solid was ﬁltered and washed with water, eth-
anol and diethyl ether and dried in vacuo over P4O10. Yield 60%. Anal.
Calc. for C15N4H7F15PtCl2: C, 22.68; H, 0.89; N, 7.05; Cl, 8.93; Pt,
24.56%. Found: C, 23.00; H, 0.97; N, 7.23; Cl, 8.46; Pt, 24.90%. Melting
point: N350 °C (decomp.). ΛM = 1.75 Ω−1 cm2 mol−1 (indicative of
neutral complex) [33]. IR (cm−1) for the complex 1592 v(CH_N),
1658 v(C_N), 1242–1147 v(C–F), 343, 320 v(Pt–Cl), 272 v(Pt–N).
1H NMR for the complex (DMSO, 300 MHz) δ ppm: 8.85 (d, 1H,
C6HC6ʹH), 8.22 (d, 1H, C3HC3ʹH), 8.11 (dt, 1H, C5HC5ʹH), 7.68 (dt,
1H, C4HC4ʹH), 4.44 (s, 3H, Me); 3JC6ʹHC5ʹH = 5.4 Hz; 3JC4ʹHC3ʹH =
9.3 Hz, 3JC5ʹHC4ʹH = 1.9 Hz.
2.3.5. [PtCl2(pfptp)2]·1.5 DMSO (5a)
The complex 5awasprepared following the general procedure. Yield
80%. Anal. Calc. for (C24H20N8F14PtCl2SO)·0.5 DMSO: C, 28.88; H, 2.23;
N, 10.78; S, 4.63; Cl, 6.82; Pt, 18.77%. Found: C, 29.28; H, 1.85; N,
11.18; S, 4.27; Cl, 6.42; Pt, 19.17%. Melting point: N350 °C (decomp.).
ΛM = 1.47 Ω−1 cm2 mol−1 (indicative of neutral complex) [33]. IR
(cm−1) for free ligand: 1590 v(CH_N), 1242–1147 v(C–F), and for
the complex 1649–1665 v(C_N), 1592 v(CH_N), 1242–1147 v(C–F),
1032 v(S_O), 333, 322 v(Pt–Cl), 271 v(Pt–N). 1H NMR for the complex
(DMSO, 300 MHz) δ ppm: 8.80 (d, 2H, C6HC6ʹH), 8.19 (d, 2H, C3HC3ʹH),
8.03 (t, 2H, C5HC5ʹH), 7.62 (t, 2H, C4HC4ʹH), 4.39 (s, 3H, CH3), 2.52–2.55
(s, non-coord. DMSO); 3JC6ʹHC5ʹH = 5.2 Hz; 3JC4ʹHC3ʹH = 9.3 Hz;
3JC5ʹHC4ʹH = 6.0 Hz.
2.4. Biological studies
2.4.1. Viability assay in vitro
Synthesized platinum(II) complexes and relative ligands were
dissolved in dimethylsulfoxide (DMSO) and then diluted in culture
medium so that the effective DMSO concentration did not exceed
0.1%. HepG2, MCF-7 and HTC116 and Caco-2 (human colorectalcarcinoma) cell lines were purchased from American Type Culture
Collection, Rockville, MD, USA. All of them were grown in Roswell
Park Memorial Institute (RPMI) medium supplemented with L-
glutamine (2 mM), 10% fetal bovine serum (FBS), penicillin (100
U/ml), streptomycin (100 μg/ml) and gentamicin (5 μg/ml). HepG2
culture medium also contained sodium pyruvate (1.0 mM). Cells
were maintained in log phase by seeding twice a week at a density
of 3 × 108 cells/l in humidiﬁed 5% CO2 atmosphere, at 37 °C. In all ex-
periments, cells were made quiescent through overnight incubation
before the treatment with the compounds or vehicle alone (control
cells) whereas Caco-2 cells were treated 15 days after conﬂuence, at
which time the cells are differentiated in normal intestinal-like cells
[34]. No differences were found between cells treated with DMSO
0.1% and untreated cells in terms of cell number and viability.
Cytotoxic activity of the platinum(II) complexes against human
tumor cell lines (HepG2, MCF-7 and HCT116) and intestinal-like differ-
entiated cells (Caco2) was determined by the MTT colorimetric assay
based on the reduction of 3-(4,5-dimethyl-2-thiazolyl)bromide-2,5-
diphenyl-2H-tetrazolium to purple formazan by mitochondrial dehy-
drogenases of living cells. This method is commonly used to illustrate
inhibition of cellular proliferation. Monolayer cultures were treated
for 24 h with various concentrations (0.1–100 μM) of the drugs. Cis-
platin and ligands were used for comparison. Brieﬂy, all cell lines
were seeded at 2 × 104 cells/well in 96-well plates containing
200 μl RPMI. When appropriated, cells were washed with fresh
medium and incubated with the compounds in RPMI. After 24 h in-
cubation, cells were washed, and 50 μl FBS-free medium containing
5 mg/ml MTT were added. The mediumwas discarded after 2 h incu-
bation at 37 °C by centrifugation, and formazan blue formed in the
cells was dissolved in DMSO. The absorbance, measured at 570 nm
in a microplate reader (Bio-RAD, Hercules, CA), of MTT formazan of
control cells was taken as 100% of viability. IC50 value for each
Table 2
Cell survival of tumor cells treated for 24 h with the ligands 2 and 4, relative to vehicle
control.
Ligand HepG2 MCF7 HCT116
Cell viability (% of control)
2 10 μM 98 ± 2 97 ± 3 100 ± 2
100 μM 99 ± 3 98 ± 4 97 ± 5
4 10 μM 96 ± 3 97 ± 3 98 ± 4
100 μM 82 ± 4⁎ 88 ± 4⁎ 75 ± 5⁎
Values are the mean ± SD of two separate experiments carried out in triplicate.
⁎ Signiﬁcantly different from the relevant control with P b 0.05 (Student's t-test).
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ity versus concentration and reading off the concentration at which
50% of cells remained viable relative to the control. Each experiment
was repeated at least three times in triplicate to obtain the mean
values. In selected experiments, MTT test was carried out also on
cells treated with the compounds for 48 or 72 h.Fig. 4. Flow cytometric analysis for the quantiﬁcation by AnnexinV/PI double staining of comple
were incubated for 24 h in the absence (control) or in the presence of individual complexes and
(AnnexinV−/PI-); 4, cells in early apoptosis (AnnexinV+/PI-); 2, cells in tardive apoptosis (Ann
iments with comparable results.2.4.2. Measurement of phosphatidylserine exposure
The externalization of phosphatidylserine (PS) to the cell surface
was detected by ﬂow cytometry by double staining with Annexin V-
FITC/PI. Phosphatidylserine, which is normally located on the cytoplas-
mic surface of cell membranes, is exposed on the cell surface upon in-
duction of apoptosis. Annexin V binds to phosphatidylserine and is
used to identify the earliest stage of apoptosis. PI, which does not
enter cells with intact membranes, is used to distinguish between
early apoptotic cells (Annexin V-FITC positive and PI negative) and
late apoptotic cells (Annexin V-FITC/PI-double positive). Tumor cells
(HepG2, MCF-7 and HCT116) were seeded in triplicate in 24-wells cul-
ture plates at a density of 5.0 × 104 cells/cm2. After an overnight incuba-
tion, the cells were washed with fresh medium and incubated with the
compounds in RPMI. After 24 h, cells were harvested by trypsinization
and adjusted at 1.0 × 106 cells/ml with combining buffer according to
the manufacturer's instructions (eBioscience, San Diego, CA). 100 μl of
cell suspended solution was added to a new tube, and incubated with
Annexin V-FITC and PI solution at room temperature in the dark for
15 min. Then samples of at least 1.0 × 104 cells were subjected toxes 2a or 4b induced apoptosis in HepG2 (A), MCF-7 (B) and HCT116 (C). Cell monolayers
submitted to double stainingwith Annexin V/PI as reported in Experimental. 3, viable cells
exinV+/PI+); 1, necrotic cells (AnnexinV−/PI+). Representative images of three exper-
98 S. Rubino et al. / Journal of Inorganic Biochemistry 155 (2016) 92–100ﬂuorescence-activated cell sorting (FACS) analysis by Epics XL™ ﬂow
cytometer using Expo32 software (Beckman Coulter, Fullerton, CA),
using appropriate 2-bidimensional gating method.2.4.3. Acridine orange and ethidium bromide morphological ﬂuorescence
dye staining
AO stains DNA bright green, allowing visualization of the nuclear
chromatin pattern and stains both live and dead cells. EB stains DNA or-
ange but is excluded by viable cells. Dual staining allows separate enu-
meration of populations of viable non apoptotic, viable (early)
apoptotic, nonviable (late) apoptotic, and necrotic cells. Live cells ap-
pear uniformly green. Early apoptotic cells stain green and contain
bright green dots in the nuclei as a consequence of chromatin condensa-
tion and nuclear fragmentation. Late apoptotic cells incorporate EB and
therefore stain orange, but, in contrast to necrotic cells, the late apopto-
tic cells show condensed and often fragmented nuclei. Necrotic cells
stain orange, but have a nuclear morphology resembling that of viable
cells, with no condensed chromatin. Brieﬂy, after tumor cells (HepG2,
MCF-7 andHCT116)were treatedwith the compounds for 24 h, theme-
dium was discarded. Cells were washed with saline 5 mM phosphate
buffer (PBS) and then incubated with 100 μl PBS containing 100 μg/ml
of EB plus 100 μg/ml of AO. After 20 s, EB/AO solution was discarded
and cells immediately visualized by means of ﬂuorescent microscope
equipped with an automatic photomicrograph system (Leica, Wetzlar,
Germany). Multiple photos were taken at randomly selected areas of
the well to ensure that the data obtained are representative.Fig. 5. Fluorescencemicrographs of EB/AOdouble stainedHepG2 (A),MCF-7 (B) andHCT116 (C
(control) or in the presence of individual complexes and submitted to double stainingwith EB/A
of three experiments with comparable results (200× magniﬁcation).3. Results and discussion
3.1. IR spectra
The IR spectra of 2, 3, 4 and 5 free ligands show two characteristic
bands due to v(CH_N) of pyridine rings at ca. 1590 cm−1, v(C_N) at
ca. 1630 of 1,2,4-oxadiazole [35,22], and at 1649–1665 of 1,2,4-triazole.
The band of v(C–F) vibration of perﬂuoroalkyl chains occurs at 1214–
1150 cm−1 for the ligand 2; and at 1223–1159 cm−1 for 3. In 1,2,4-tri-
azole ligands, the bands occur at 1240–1147 cm−1 for 4 and 5. In the
complexes, the bands are shifted at 1584 cm−1 v(CH_N) and 1241–
1144 cm−1 v(C–F) for 2a and at 1216–1157 cm−1 v(C–F) for 3a indicat-
ing that the ligandswere present in the complexes; in fact the bands are
shifted for complexation of the ligand to theplatinum ion [35]. The pres-
ences of v(Pt–Cl) at 342 and 326 cm−1 and at 333 e 320 cm−1 in the 2a
and 3a complexes respectively, were due to Pt–Cl stretching vibrations.
Moreover the observed bands at 279 and 256 cm−1 in 2a and 3a respec-
tively, can be assigned to stretching vibrations of Pt–N bond [36–38].
The presence of non-coordinated molecules of solvate DMSO in both
2a and 3a is conﬁrmed by a signal at 1023 cm−1 [38]. The vibration
bands v(CH_N) and v(C–F) at ca 1590 cm−1 and at 1242–1147 cm−1
respectively conﬁrmed the presence of the ligand in 4a, 4b and 5a com-
plexes. The spectra showed also symmetrical and asymmetrical
stretching bands of Pt–Cl bond at 338, 312 cm−1 for 4a, at 343,
320 cm−1 for 4b and at 333, 322 cm−1 for 5a, indicating a cis-square
planar arrangement of the platinum(II) via chloride ions; v(Pt-N) vibra-
tions occur at 277, 272 and 271 cm−1 for 4a, 4b and 5a respectively. In) cells after treatmentwith complexes 2a or4b. Cellswere incubated for 24h in the absence
Oas reported in Experimental.Arrows indicatemembraneblubbing. Representative images
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vate) DMSO in the range 1032–1037 cm−1 [39].
3.2. NMR spectra
The coordination mode of the complexes in solution was deter-
mined by using the 1H NMR spectra and the assignments of resonances
were based on literature data [40,9] and are in good agreement with
proposed structure. The numbering of protons used for 1H NMR is
shown in Scheme 2. The four proton signals of pyridine coordinated to
Pt(II) ion for 2a and 3a complexes are shifted downﬁeld compared to
the free ligands. In the ligands, signals are observed in the range 8.79–
7.6 ppm for 2a and at 8.85–7.72 ppm for 3a; in theﬁrst and second com-
plex doublets are assigned to C6ʹH and C3ʹH and double of triplet and
multiplet to C5ʹH and C4ʹH respectively. Therefore the coordination of
the ligand can be ascribed to the N1 atom of pyridine acting as
monodentate, being the proton C6ʹH the most shifted, as reported for
similar complexes with Mn(II) and Co(II) ions [41]. The presence of a
singlet for 2a at 2.65 ppm and for 3a at 2.53 ppm close to the solvent
DMSO-d5 multiplet is attributed to the non-coordinated (solvate)
DMSO [39]. The 1H NMR resonances of 4a, 4b and 5a complexes show
a slight shift to down ﬁeld of pyridine protons as compared to the unco-
ordinated ligands 4 and 5. The doublet at 8.85 ppm can be attributed to
the proton C6ʹH for 4a and 4b complexes and it is slightly shifted as com-
pared with the proton C6ʹH (8.80 ppm) of the free ligand. Another dou-
blet at 8.22 ppmcan be assigned to proton C5ʹH,while two triplets for 4a
and two doublet of triplets for 4b at 8.11 and 7.68 ppm, can be assigned
to C3ʹH and C4ʹH respectively. The singlet at 4.44 ppm of the methyl
group of 1,2,4-triazole is also slightly shifted compared to uncoordinat-
ed ligand (4.39 ppm). The presence in 4a of a singlet signal in the range
2.61–2.57 is due to non-coordinated DMSO. Coordination of Pt(II) ion to
the ligand for 4a, occurs via N2 atoms of two 1,2,4-triazole moieties and
its coordination is completed by PtCl2 moiety. On the contrary for 4b
only one molecule of 1,2,4-triazole is coordinated to Pt(II) ion via N4
atom of triazole and N1 atom of pyridine, where the remaining two co-
ordination sites of the platinum are engaged with two chlorine atoms.
Similar complexes with 6-(5-triﬂuoromethyl-1,2,4-triazol-3yl)-4,4′-di-
methyl-2,2′-bipyridine ligand have been reported [42]. In the complex
4a and 5a the coordination environment of Pt(II) ion is equal and the
resonance signals of the pyridine protons are not shifted with respect
to the ligand and they occur in the range 8.80–7.62 ppm.
3.3. Biology
Cytotoxicity in vitro of the synthesized platinum(II) complexes was
evaluated byMTT on three tumor human cell lines: HepG2, HTC116 and
MCF-7. After 24 h of incubation, a clear dose dependent inhibitory effect
of 2a and 4b on the viability of all the studied cancer cell lines wasmea-
sured, whereas far less cytotoxicity of 3a, 4a and 5a was noticeable
(Fig. 1). Prolonged incubation times (48–72 h) with 2a and 4b resulted
in a progressive cell growth inhibition, indicating antiproliferative activ-
ity of the compounds (Fig. 2). Table 1 reports the concentration of 2a
and 4b required to inhibit 50% of cell proliferation after 24 h of treat-
ment, when compared to untreated cells (IC50), in comparison with cis-
platin assayed in the same experimental conditions. The calculated IC50
values show that anti-proliferative activity of both the cisplatin analogs
was comparable to that observed with cisplatin, being 2a signiﬁcantly
more efﬁcacy than 4b against all the selected cancer cells. Under identi-
cal conditions, both the platinum(II) complexes did not substantially
impaired viability of intestinal normal-like differentiated Caco-2 cells,
suggesting high selectivity towards tumor cells (Fig. 3). Eventual contri-
bution of the ligand to the cytotoxic activity of 2a and 4bwas assessed
by MTT after treatment for 24 h of the tumor cell lines with 2 or 4,
respectively, at 10 and 100 μM. While 2 did not affect cell viability
at any assayed concentration, a slight but signiﬁcant decrement
(P b 0.05) of the cell proliferation of all selected tumor lines wasmeasured with compound 4 at 100 μM (Table 2). Mechanism of the
anti-proliferative effect (necrosis or apoptosis) of 2a and 4bwas inves-
tigated by double staining with PI and Annexin V-FITC followed by
cytoﬂuorimetric analysis. The chosen concentrations were selected on
the basis that they represented the IC50 values measured at 24 h for
each cell line, as reported in Table 1. Fig. 4 shows that both the com-
pounds did not exert necrotic effects in any cancer cell line, while in-
duced a clear shift of viable cells towards early apoptosis in HepG2
and HCT116 or towards late apoptosis in MCF-7 cells. To conﬁrm apo-
ptoticmechanismof cytotoxicity of the studied platinum(II) complexes,
we carried out morphological evaluation of the HepG2, HCT116 and
MCF-7 tumor cells using AO and EB double staining. After 24 h of treat-
ment with 2a or 4b at IC50 concentration, ﬂuorescent microscopy re-
vealed the appearance of cells containing bright green patches in the
nuclei as a consequence of chromatin condensation and nuclear frag-
mentation, which are typical features of apoptosis. Moreover, ﬂuoresc-
ing orange cells owing to increase of cell permeability to ethidium
bromide, cell shrinkage and nuclear fragmentation were also evident
as cells in late apoptosis, chieﬂy inMCF-7 cell line (Fig. 5). Taken togeth-
er, these ﬁndings provided strong evidence that both the cisplatin ana-
logs induced apoptosis in the studied tumor cell lines.
4. Conclusions
The ligands 5-perﬂuoroalkyl-1,2,4-oxadiazole and 3-perﬂuoroalkyl-
1,2,4-triazole and theirmetal complexes 2a, 3a, 4a, 4b, 5awith Pt(II) ion
have been synthesized and characterized by the combination of
elemental analysis, atomic absorption spectrometer, 1H NMR, IR, and
molar conductivities. In the complexes 2a and 3a, the ligands 5-
perﬂuoroalkyl-1,2,4-oxadiazole bind to Pt(II) ion in a monodentate
way through the pyridine ring where the geometry of metal is square
planar. In 4a and 5a the 3-perﬂuoroalkyl-1,2,4-triazole ligands also act
as monodentate to Pt(II) ion through N2 atom of the 1,2,4-triazole
ring. Instead, in 4b the coordination of the ligand to themetal ion occurs
in a bidentatemode. The ﬁve new complexes and their new ligands syn-
thesized have been tested in vitro. The complexes 2a and 4b and only
one ligand 2 were found to be active towards the engaged three
tumor cell lines, but 2awas found to bemuchmore active than its ligand
2. A tentative examination of a qualitative structure–activity relation-
ship indicates that the biological activity of the new family of Pt(II) com-
plexes depends on the length of the perﬂuoroalkyl chain; in fact, the
most active complexes are those with pfhop and pfhtp ligands; this
fact could be ascribed to an enhanced lipophilicity of the longest
perﬂuoroalkyl chain that could affect the cell membrane permeation.
The geometry of Pt(II) is square-planar and the planarity of the com-
plexes was suggested to be essential for antitumor activity, and proba-
ble intercalation with DNA [43]; this fact could suggest an explanation
for the lack of bioactivity of complexes 4a and 5a, that being more hin-
dered, twist the planarity of the complex.
Furthermore, the complex 4bwith respect to 4a has only one ligand
moiety, so that around Pt(II) ion there is less steric hindrance, therefore
4b is more available to the formation of DNA binding.
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Appendix A. Supplementary data
Supporting Information: 1H NMR spectra for compounds 2–5 are re-
ported in Figs. S1–S4, GC–MS chromatogram andMS spectra associated
for compounds 2–5 are reported in Figs. S5–S8 respectively. Supple-
mentary data associatedwith this article can be found in the online ver-
sion, at doi: http://dx.doi.org/10.1016/j.jinorgbio.2015.11.020.
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